Cancer Letters
Volume 297, Issue 1 , Pages 65-74 , 1 November 2010

RXRγ and PPARγ ligands in combination to inhibit proliferation and invasiveness in colon cancer cells

  • Alessio Papi

      Affiliations

    • Department of Experimental Evolutionary Biology, University of Bologna, via Selmi, 3, 40126 Bologna, Italy
    • Corresponding Author InformationCorresponding author. Tel.: +39 0512094131.
    • ,
  • Paola Rocchi

      Affiliations

    • Department of Experimental Pathology, viale Filopanti, 22, University of Bologna, 40126 Bologna, Italy
    • ,
  • Anna Maria Ferreri

      Affiliations

    • Department of Experimental Pathology, viale Filopanti, 22, University of Bologna, 40126 Bologna, Italy
    • ,
  • Marina Orlandi

      Affiliations

    • Department of Experimental Evolutionary Biology, University of Bologna, via Selmi, 3, 40126 Bologna, Italy

Received 15 March 2010 ,Revised 21 April 2010 ,Accepted 27 April 2010.

References 

  1. Segal NH, Saltz LB. Evolving treatment of advanced colon cancer. Annu. Rev. Med. 2009;60:207–219
  2. Banu N, Buda A, Pignatelli SM. Inhibition of COX-2 with NS-398 decreases colon cancer cell motility through blocking epidermal growth factor receptor transactivation: possibilities for combination therapy. Cell Proliferat. 2007;40:768–779
  3. Annie L, Diana M, Stafforini DM. The role of cyclooxygenase-2 and prostaglandins in colon cancer. Prostag. Other Lipid Mediat. 2007;82:147–154
  4. Byun JH, Lee MA. Association between cyclooxygenase-2 and matrix metalloproteinase-2 expression in non-small cell lung cancer. Jpn. J. Clin. Oncol. 2006;36:263–268
  5. Teri L, Larkins L, Gary L. Sanford inhibition of cyclooxygenase-2 decreases breast cancer cell motility, invasion and matrix metalloproteinase expression. BMC Cancer. 2006;6:181
  6. Castellino RC, Durden DL. Mechanisms of disease: thePI3K–Akt–PTEN signaling node – an intercept point for the control of angiogenesis in brain tumors. Nat. Clin. Pract. Neurol. 2007;3:682–693
  7. Clark IM, Swingler TE, Edwards DR. The regulation of matrix metalloproteinases and their inhibitors. Int. J. Biochem. Cell Biol. 2008;40:1362–1378
  8. Clarke N, Germain P, Gronemeyer H. Retinoids: potential in cancer prevention and therapy. Expert Rev. Mol. Med. 2004;30:1–23
  9. Kagechica H, Shudo K. Synthetic retinoids: recent development concerning structure and clinical utility. J. Med. Chem. 2005;48:5875–5883
  10. Orlandi M, Dal Monte P, Bartolini G. Retinoids and cancer: antitumoral effects of ATRA, of 9-cis-RA and of the new retinoid IIF on HL-60 leukemic cell line. Med. Princ. Pract. 2003;12:164–169
  11. Bartolini G, Orlandi M, Papi A. Search for multidrug resistance modulators: effects of retinoids in human colon carcinoma cells. In Vivo. 2006;20:729–733
  12. Papi A, Bartolini G, Orlandi M. Inhibitory effects of retinoic acid and IIF on growth, migration and invasiveness in U87MG human glioblastoma cell line. Oncol. Rep. 2007;18:1015–1021
  13. Bartolini G, Orlandi M, Ferreri AM. Growth inhibition and proapoptotic activity induction by IIF and valproic acid on RA-resistant leukemia cells. Anticancer Res. 2008;28:283–288
  14. Papi A, Rocchi P, Orlandi M. Enhanced effects of PPARγ ligands and RXR selective retinoids in combination to inhibit migration and invasiveness in cancer cells. Oncol. Rep. 2009;21:1083–1089
  15. Papi A, Terwel D, Heneka MT. PPARgamma and RXRligans act sinergistically as potent antineoplastic agents in vitro and in vivo glioma models. J. Neurochem. 2009;109:1779–1790
  16. Germain P, Mangelsdorf DJ, Gronemeyer H. Retinoid X receptors. Pharmacol. Rev. 2006;58:760–772
  17. Yamazaki K, Weinstein IB, Moriwaki H. Synergistic effects of RXR alpha and PPAR gamma ligands to inhibit growth in human colon cancer cells–phosphorylated RXR alpha is a critical target for colon cancer management. Gut. 2007;56:1557–1563
  18. Konopleva M, Elstner E, Andreff M. PPAR and retinoid X receptor ligands are potent inducers of differentiation and apoptosis in leukemias. Mol. Cancer Ther. 2004;3:1249–1262
  19. Meade EA, Zimmerman GA, Prescott SM. Peroxisome proliferators enhance cyclooxygenase-2 expression in epithelial cells. J. Biol. Chem. 1999;274:8328–8334
  20. Fiatte C, Domenjoud L, Schohn H. Genetic analysis of peroxisome proliferator-activated receptor gamma1 splice variants in human colorectal cell lines. Int. J. Oncol. 2006;1601–1610
  21. Yaacob NS, Darus HM, Norazmi MN. Modulation of cell growth and PPARgamma expression in human colorectal cancer cell lines by ciglitazone. Exp. Toxicol. Pathol. 2008;60:505–512
  22. Lin MS, Chen WC, Wang YD. Activation of peroxisome proliferator-activated receptor gamma inhibits cell growth via apoptosis and arrest of the cell cycle in human colorectal cancer. J. Dig. Dis. 2007;8:82–88
  23. Grommes C, Landreth GE, Heneka MT. Antineoplastic effects of peroxisome proliferator-activated receptor γ agonists. Lancet Oncol. 2004;5:419–429
  24. Allred CD, Kilgore MW. Selective activation of PPARgamma in breast, colon, and lung cancer cell lines. Mol. Cell Endocrinol. 2005;12:21–29
  25. Han S, Roman J. Peroxisome proliferator-activated receptor gamma: a novel target for cancer therapeutics?. Anticancer Drugs. 2007;8:237–244
  26. Cesario RM, Stone J, W Lamph W. Differentiation and growth inhibition mediated via the RXR: PPARgamma heterodimer in colon cancer. Cancer Lett. 2006;240:225–233
  27. Shimizu M, Moriwaki H. Synergistic effects of PPAR gamma ligands and retinoids in cancer treatment. PPAR Res. 2008;181047
  28. Zoli W, Ricotti L, Amadori D. In vitro preclinical models for a rational design of chemotherapy combinations in humans tumors. Crit. Rev. Oncol./Hematol. 2001;37:69–82
  29. Delage B, Rullier A, Cassand P. The effect of body weight on altered expression of nuclear receptors and cyclooxygenase-2 in human colorectal cancers. Nutr. J. 2007;6:6–20
  30. Kraus S, Arber N. Inflammation and colorectal cancer. Curr. Opin. Pharmacol. 2009;4:405–410
  31. Yang WL, Frucht H. Activation of the PPAR pathway induces apoptosis and COX-2 inhibition in HT-29 human colon cancer cells. Carcinogenesis. 2001;22:1379–1383
  32. Pierzchalski P, Konturek SJ, Gonciarz M. Molecular mechanism of protection against chemically and gamma-radiation induced apoptosis in human colon cancer cells. J. Physiol. Pharmacol. 2008;59:191–202
  33. Ijpenberg A. In vivo activation of PPAR target genes by RXR homodimers. EMBO J. 2004;23:2083–2091
  34. Freemantle S. The retinoic acid paradox in cancer chemoprevention. J. Natl. Cancer. 2006;7:426–428
  35. Park EY, Wilder ET, Lane MA. Retinol inhibits the invasion of retinoic acid-resistant colon cancer cells in vitro and decreases matrix metalloproteinase mRNA, protein, and activity levels. Nutr. Cancer. 2007;57:66–77
  36. Kong G, Brown PH. The retinoid X receptor-selective retinoid, LGD1069, down-regulates cyclooxigenase-2 expression in human breast cells through transcription factor crosstalk: implications for molecular-based chemoprevention. Cancer Res. 2005;65:3462–3469

PII: S0304-3835(10)00241-7

doi: 10.1016/j.canlet.2010.04.026

Cancer Letters
Volume 297, Issue 1 , Pages 65-74 , 1 November 2010

Article Tools

* Image Usage & Resolution